Kenvue Inc. $KVUE Stock Holdings Lessened by Moors & Cabot Inc.

Moors & Cabot Inc. trimmed its stake in Kenvue Inc. (NYSE:KVUE) by 93.2% in the fourth quarter, Holdings Channel.com reports. The firm owned 21,312 shares of the company’s stock after selling 291,810 shares during the quarter. Moors & Cabot Inc.’s holdings in Kenvue were worth $368,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in KVUE. Cornerstone Planning Group LLC lifted its position in shares of Kenvue by 705.2% in the third quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after purchasing an additional 1,361 shares in the last quarter. Physician Wealth Advisors Inc. lifted its position in shares of Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after purchasing an additional 618 shares in the last quarter. Elyxium Wealth LLC purchased a new stake in shares of Kenvue in the fourth quarter worth approximately $26,000. SBI Securities Co. Ltd. lifted its position in shares of Kenvue by 82.4% in the fourth quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock worth $39,000 after purchasing an additional 1,027 shares in the last quarter. Finally, Atlantic Union Bankshares Corp grew its stake in Kenvue by 184.1% in the third quarter. Atlantic Union Bankshares Corp now owns 2,619 shares of the company’s stock valued at $43,000 after purchasing an additional 1,697 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Kenvue

In other news, General Counsel Matthew Orlando sold 38,491 shares of Kenvue stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.59% of the company’s stock.

Kenvue Trading Up 0.6%

Shares of KVUE opened at $17.39 on Tuesday. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $23.78. The company has a current ratio of 0.98, a quick ratio of 0.70 and a debt-to-equity ratio of 0.67. The stock has a 50 day simple moving average of $17.40 and a 200-day simple moving average of $17.47. The stock has a market cap of $33.38 billion, a PE ratio of 20.45, a PEG ratio of 1.31 and a beta of 0.55.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The business had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $3.84 billion. During the same period in the prior year, the firm posted $0.24 EPS. Kenvue’s quarterly revenue was up 4.5% compared to the same quarter last year. On average, sell-side analysts predict that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were paid a $0.2075 dividend. This represents a $0.83 annualized dividend and a dividend yield of 4.8%. The ex-dividend date of this dividend was Wednesday, May 13th. Kenvue’s dividend payout ratio (DPR) is 97.65%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on KVUE. UBS Group lowered their target price on Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 7th. Weiss Ratings downgraded Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday. Argus upgraded Kenvue to a “hold” rating in a research note on Friday, March 6th. Zacks Research upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 8th. Finally, Canaccord Genuity Group boosted their target price on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research note on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $19.33.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.